看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
& Z" `5 H+ {# t8 R9 d+ b8 C) o2 Z
) P8 b! K- {$ U, u3 I
8 e# k: C P, @2 Q7 I/ C6 PCurrently available feasibility data for possible combination strategies. 3 g8 z8 t$ V% W4 V _! j$ W
————————————————————————————————) @: ^, n/ `; [4 `
Combination Feasibility according to preliminary data
" l2 K. f' m' ^- S——————————————————————————————————" n+ s: r0 K, A9 P- I
Bevacizumab + sorafenib Yes, reduced dose
/ H0 ^. D, g& Y* e; L2 n1 O& r5 D+ ZBevacizumab + sunitinib† No ' b# c: ~5 T. g
Bevacizumab + temsirolimus Yes
0 ~% _) K6 c% mBevacizumab + everolimus Yes R! P% S$ j7 S# r5 ^: U4 A3 z6 {5 _
Sorafenib + sunitinib ?
$ ?+ T$ R4 i4 iSorafenib + temsirolimus Yes, reduced dose [5 `* B$ g$ z1 Z2 V* P4 B* f
Sorafenib + everolimus Yes, reduced dose
+ j. s/ b! B4 f r, n. Q1 c% F9 sSunitinib + temsirolimus† No
. I& P& |8 B2 `% ]; B- p, GSunitinib + everolimus ? - ?6 ~1 x, u5 x0 J$ ?
Temsirolimus + everolimus ? 2 U2 v' {$ o: Q' p( b6 H
————————————————————+ |: L3 u5 O2 `1 a* ^9 I- t$ I
†Led to US FDA warning.3 [# J& }2 s5 w1 n
?: As yet unattempted combination.
2 r0 x2 r! T; c; ~ |
显身卡
' ^: | D# x8 ]! Y! N
